Medtronic Q3 2026 Earnings Analysis

# Beta Finch Podcast Script - Medtronic Q3 2026 Earnings**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we turn complex quarterly reports into clear insights. I'm Alex.**JORDAN**: And I'm Jordan. Today we're diving into Medtronic's Q3 2026 results, and wow - this was quite the quarter for the medical device giant.**ALEX**: Before we jump in, I need to share our mandatory disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.**JORDAN**: Right, thanks Alex. So Medtronic - ticker MDT - just reported some pretty impressive numbers. Let's start with the headline figures. Revenue hit $9 billion, growing 8.7% reported and 6% organically. That's actually a 50 basis point acceleration from the prior quarter.**ALEX**: And they beat their own guidance by 50 basis points too. The real star here was their cardiovascular portfolio, which grew 11% year-over-year - that's the strongest growth they've seen in cardiovascular in the last ten years, excluding COVID comps.**JORDAN**: The standout within cardio was their Cardiac Ablation Solutions, or CAS business, which includes their pulse field ablation technology. This grew 80% year-over-year, with PFA accounting for 80% of that revenue. CEO Geoffrey Martha seems really excited about this - they're calling it one of their "generational growth drivers."**ALEX**: Speaking of growth drivers, Medtronic is really pushing four major ones: their PFA technology, the Simplicity Spyral system for hypertension, Altaviva for urinary incontinence, and their Hugo surgical robot. Jordan, what caught your attention in the management commentary?**JORDAN**: What's fascinating is how they're building entirely new markets. Take their Simplicity system for hypertension - they launched a direct-to-consumer campaign called "Go Beyond" and saw website visits jump from 50,000 in Q2 to 2.5 million in Q3. That's a 50x increase! They opened over 200 new accounts this quarter and now have about 100 million covered lives, which is roughly one-third of the US population.**ALEX**: That consumer demand story is really compelling. And it sounds like they're seeing great patient outcomes, which is driving physician excitement. But let's talk numbers - what about profitability?**JORDAN**: Adjusted EPS came in at $1.36, beating the midpoint of guidance by 3 cents. However, gross margins are taking a hit from business mix - specifically from CAS and their Diabetes business. CFO Thierry Pieton explained that CAS currently has an unfavorable mix of lower-margin capital equipment to higher-margin catheters, since they're still in early launch phase.**ALEX**: But that should improve over time as the installed base grows and catheter sales increase relative to the initial capital equipment, right?**JORDAN**: Exactly. Pieton said they expect to see that mix inflection in the second half of next year, with CAS actually driving gross margin improvement as early as fiscal 2027. There's also the Diabetes business separation they're planning - since Diabetes has lower margins than the rest of the business, spinning it off should provide a natural margin lift.**ALEX**: Let's talk about that guidance for fiscal 2027. They're maintaining their expectation for high-single-digit EPS growth, but there are some moving pieces.**JORDAN**: Right, there are several puts and takes. They'll have a full year of tariff impact - about $300 million versus $185 million in 2026. There's an extra selling week that will help growth. And the Diabetes separation will create some temporary dilution of 1-2 cents per month between the IPO and the full split, since they lose 20% of Diabetes profits but don't get the share buyback benefit until the full separation.**ALEX**: The Q&A session had some interestThis episode includes AI-generated content.